Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Key Points

• Ultragenyx Pharmaceutical reported a quarterly earnings per share of ($1.17), surpassing analysts' expectations by $0.10.
• The company's stock price rose 1.5% to $28.88 following the earnings release, with a trading volume of over 1.4 million shares.
• Analysts maintain a mostly positive outlook, with a Moderate Buy rating and an average price target of $83.08 for the stock.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10, Zacks reports. Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. Ultragenyx Pharmaceutical updated its FY 2025 guidance to EPS.

Ultragenyx Pharmaceutical Stock Up 1.5%

RARE stock traded up $0.42 during trading on Tuesday, reaching $28.88. The stock had a trading volume of 1,423,467 shares, compared to its average volume of 1,271,680. Ultragenyx Pharmaceutical has a one year low of $25.81 and a one year high of $60.37. The company's 50 day moving average is $33.84 and its two-hundred day moving average is $37.07. The company has a market capitalization of $2.73 billion, a price-to-earnings ratio of -4.91 and a beta of 0.25.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is currently owned by insiders.

Institutional Trading of Ultragenyx Pharmaceutical

A hedge fund recently raised its stake in Ultragenyx Pharmaceutical stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 14.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 232,360 shares of the biopharmaceutical company's stock after buying an additional 29,984 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned about 0.25% of Ultragenyx Pharmaceutical worth $8,414,000 at the end of the most recent quarter. 97.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RARE. Wells Fargo & Company lowered their target price on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an "outperform" rating and a $65.00 target price for the company. Wedbush lowered their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 target price for the company in a research note on Monday, July 28th. Finally, Guggenheim reissued a "buy" rating and set a $64.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 20th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $83.08.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.